XLIFE-SCIENCES-AG
5.3.2021 08:50:09 CET | Business Wire | Press release
Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology platform for the development of antibodies will be used even more efficiently.
As of today, Xlife Sciences AG has already identified 30 compounds with blockbuster potential with its antibody screening platform. These therapeutic antibodies have already shown to be safe and effective in humans. Xlife can modify these antibodies with utmost accuracy and increase the quality of the active ingredient. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profile for cancer therapy. The target market potential of the pre-selected antibodies is in the range of several billion US dollars.
With the collaboration of abc biopply, a portfolio company of anfass Life Technologies, the development process will be advanced significantly. Abc biopply developed a technology platform 3D CoSeedis(TM) that allows the testing and characterization in terms of efficacy of antibodies in 3D- cell cultures, also known as organoids, which are similar to animal or human tissue. This reduces or even eliminates animal testing and accelerates product development significantly. 3D CoSeedis(TM) differentiates itself with its unique homogeneity of produced spheroids and allows standardized mass production. This leads to simplified preclinical modelling of diseases. With this sustainable joint-venture, Quadira Biosciences AG could revolutionize cancer therapy.
About anfass Life Technologies AG
anfass Life Technologies AG invests in promising technologies in the fields of biotech, medical technology and diagnostics. The company also provides strategic and operational support to start-ups and SMEs in the life science sector and offers access to a broad expertise and a reliable network of selected partners. www.anfass.ch
abc biopply ag is a portfolio company of anfass Life Technologies AG. www.biopply.com
.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
IMPORTANT NOTE: The Annual General Meeting of Xlife Sciences AG will now take place on May 11, 2021, due to the Covid-19 measures of the federal government in written form by letter.
Language: |
English |
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich EQS |
News ID: |
1173329 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006227/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy9.6.2026 15:22:00 CEST | Press release
The first patient treated was a child. The milestone marks the moment upright proton therapy moves from innovation to adoption — and reflects exactly what Leo Cancer Care built Marie® to achieve Following the landmark first treatment at Stanford Medicine Cancer Center Care June 4, Leo Cancer Care today announces the role of its Marie® upright patient positioning and imaging platform in enabling the world's first compact upright proton therapy patient treatment. Delivered using the Mevion S250-FIT™ Proton Therapy System and powered by RayStation from RaySearch, the milestone is the culmination of a decade of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609870736/en/ The treatment room at Stanford Medicine Cancer Center, Palo Alto, California, housing the Marie® upright patient positioning platform by Leo Cancer Care (center foreground) integrated with the Mevion S250-FIT™ Proton Therapy System. The circular
Volante Technologies launches “Vol360i” Agentic AI at the core of payments, setting a new global standard for intelligence in banking9.6.2026 15:00:00 CEST | Press release
Agents deliver configurable, confidence-based automation and predictability to financial institutions through exception handling, routing, and SLA monitoring Volante Technologies, the global leader in Payments as a Service (PaaS), today announced that its Payments Platform and PaaS operations are now powered by its “Vol360i” Agentic AI. The core upgrade unlocks autonomous and semi-autonomous collaboration to reduce manual intervention, significantly increasing straight-through processing (STP) rates to over 95%, accelerating exception resolution, and proactively managing SLA performance. Vol360i is immediately available to Volante banking and financial institution clients, with four main operating principles guiding Volante’s agentic framework to deliver a frictionless payments experience: Prevent Agents: Eliminate failures before they occur, boosting reliability and reducing customer-impacting errors. Repair Agents: Self-healing AI fixes problems in real time, allowing operators to fo
Boomi Adds Snowflake Cortex Agents Support to Agentstudio to Enable Unified AI Agent Governance9.6.2026 15:00:00 CEST | Press release
Snowflake Cortex Agents support in Boomi Agentstudioenables joint customers to govern all their agents in a single, vendor-agnostic control tower Boomi, the data activation company for AI and an Elite Snowflake partner, today announced the launch of Snowflake Cortex Agents support for Agentstudio. This new integration, powered by Snowflake, enables organizations to monitor, manage, and govern every Cortex Agent that is part of their agentic workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609131798/en/ Boomi Adds Snowflake Cortex Agents Support to Agentstudio to Enable Unified AI Agent Governance "Customers are scaling AI agents into production, and partners are bringing new solutions to market at record speed, both powered by Boomi Agentstudio,” said Steve Lucas, Chairman and CEO at Boomi. “This dual momentum reflects the unique strength of the Boomi Enterprise Platform, empowering innovation while ensuring gove
Xsolla Brings Direct-to-Consumer Commerce Expertise to Gamesforum Hamburg 2026 With Keynote and Panel Appearances9.6.2026 14:01:00 CEST | Press release
As An Exclusive Global Partner Of The Gamesforum Series, Xsolla Takes Two Stages In Hamburg, Headlined By A Keynote With AppsFlyer On Web Shop Attribution Xsolla, a global leader in video game commerce, today announced its participation in Gamesforum Hamburg 2026, taking place June 9–10, 2026, at NORD EVENT Panoramadeck in Hamburg, Germany. As an Exclusive Global Partner of the Gamesforum series, Xsolla will bring its direct-to-consumer commerce expertise to one of Europe's leading gatherings for mobile game growth and monetization, with Jane Startseva, Vice President of Business Development, EMEA, taking the stage across two sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609166526/en/ Graphic: Xsolla Xsolla's presence in Hamburg underscores its role at the center of gaming's shift toward direct-to-consumer commerce: On June 9 at 10:00 AM, Jane joined Adam Smart, Global Director of Product – Gaming at AppsFlyer,
Duetti Expands Funding Offerings for Independent Artists With Two New Programs9.6.2026 14:01:00 CEST | Press release
Master Tracks as Young as Six Months Now Eligible for Acquisition Deals; New Remix Program Expands Collaboration Opportunities Duetti Inc. (“Duetti” or the “Company”), the music company that partners with independent artists and songwriters to buy, manage, and market their catalogs, announces today a significant expansion of its funding offering. Artists can now sell their master recording tracks, or parts thereof, in as little as six months after release - substantially earlier than the company’s prior two-year threshold. Duetti is also launching its new Remix Program, which allows independent artists to create remixes, covers, and other derivative works from Duetti’s 30,000-track catalog (across both masters and compositions). In return, artists can receive upfront cash compensation, ongoing royalty % share, 0% distribution fees, and dedicated marketing support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609063445/e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom